Yael Glickman - Nextage Therapeutics VP Devel
| MCTC Stock | ILA 80.00 6.00 8.11% |
Insider
Yael Glickman is VP Devel of Nextage Therapeutics
| Age | 57 |
| Phone | 972 73 2753450 |
| Web | http://www.m-medic.com |
Nextage Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3684) % which means that it has lost $0.3684 on every $100 spent on assets. This is way below average. Nextage Therapeutics' management efficiency ratios could be used to measure how well Nextage Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Boaz Aviv | Blender Financial Technologies | 36 | |
| Noam Barkai | Nrgene Technologies | 48 | |
| Orit Dvash | Priortech | 50 | |
| Alex Master | Scope Metals Group | N/A | |
| Amir Tzhori | Priortech | 55 | |
| Kobi Baruch | Nrgene Technologies | 47 | |
| Gil Ronen | Nrgene Technologies | 55 | |
| Ehud Belder | Nrgene Technologies | 39 | |
| Zvika CPA | Scope Metals Group | N/A | |
| David Radolsky | Nrgene Technologies | 38 | |
| Boaz Leshem | Scope Metals Group | 63 | |
| Gil CPA | Scope Metals Group | 56 | |
| Yaakov Baruch | Nrgene Technologies | 47 | |
| Tomer Hefetz | Technoplus Ventures | 51 | |
| Gilad Fishman | Scope Metals Group | 51 | |
| Alex Shatzir | Scope Metals Group | N/A | |
| Gal Aviv | Blender Financial Technologies | 43 | |
| Yana Voldman | Nrgene Technologies | N/A | |
| Stanley ADV | Scope Metals Group | N/A | |
| Moshe Eisenberg | Priortech | 56 | |
| Ramy Langer | Priortech | 69 | |
Management Performance
| Return On Asset | -0.37 |
Nextage Therapeutics Leadership Team
Elected by the shareholders, the Nextage Therapeutics' board of directors comprises two types of representatives: Nextage Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nextage. The board's role is to monitor Nextage Therapeutics' management team and ensure that shareholders' interests are well served. Nextage Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nextage Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Meir Yoeli, Chief Executive Officer | ||
| Itai BarNatan, Chief Officer | ||
| Yifftach Biel, Deputy Vice President - Finance | ||
| Yael Glickman, VP Devel | ||
| Doron Debbie, Independent Director |
Nextage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nextage Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.37 | |||
| Profit Margin | (2.30) % | |||
| Operating Margin | (9.71) % | |||
| Shares Outstanding | 2.27 M | |||
| Shares Owned By Insiders | 22.39 % | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | (91.98) X | |||
| Price To Book | 4.68 X | |||
| Price To Sales | 26.11 X | |||
| Revenue | 297 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Other Information on Investing in Nextage Stock
Nextage Therapeutics financial ratios help investors to determine whether Nextage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nextage with respect to the benefits of owning Nextage Therapeutics security.